Internet Computer
ICP
Bitcoin Cash
BCH
Litecoin
LTC
Specify a stock or a cryptocurrency in the search bar to get a summary
Internet Computer
ICP
Bitcoin Cash
BCH
Litecoin
LTC
IGM Biosciences Inc
1K0Current price
9 EUR
-0.7 EUR (-7.22%)
Last closed
11.15 USD
Company
igmbio.com
ISIN
US4495851085
Sector
Healthcare
Industry
Biotechnology
Exchange
Frankfurt Exchange
Capitalization
772 922 624 USD
Yield for 12 month
+64.41 %
1Y
3Y
5Y
10Y
15Y
1K0
IGM Biosciences, Inc., a clinical-stage biotechnology company, develops Immunoglobulin M (IgM) antibodies for the treatment of cancer and autoimmune and inflammatory diseases. It develops Aplitabart, a Death Receptor 5 Agonist IgM antibody for the treatment of colorectal cancer; imvotamab, a CD20 x CD3 bispecific IgM antibody to treat myositis, as well as for the treatment of systemic lupus erythematosus and rheumatoid arthritis that is Phase Ib clinical trial; and IGM-2644, a bispecific T cell engaging IgM antibody targeting CD38 and CD3 proteins for the treatment of autoimmune diseases. IGM Biosciences, Inc. has a collaboration and license agreement with Genzyme Corporation to generate, develop, manufacture, and commercialize IgM antibodies. The company was formerly known as Palingen, Inc. and changed its name to IGM Biosciences, Inc. in 2010. IGM Biosciences, Inc. was incorporated in 1993 and is headquartered in Mountain View, California. Address: 325 East Middlefield Road, Mountain View, CA, United States, 94043
Check your investment idea
Find the best to beat the market
TSLA
Tesla Motors
AAPL
Apple
MSFT
Microsoft
Analytics
WallStreet Target Price
19.4 USDP/E ratio
–Dividend Yield
–Current Year
+2 130 000 USD
Last Year
+1 069 000 USD
Current Quarter
+1 254 000 USD
Last Quarter
+497 000 USD
Current Year
-6 146 999 USD
Last Year
+1 069 000 USD
Current Quarter
-1 022 000 USD
Last Quarter
-1 679 000 USD
Key Figures 1K0
1 year
3 years
5 years
10 years
EBITDA
-226 374 000 USD
Operating Margin TTM
PE Ratio
–
Return On Assets TTM
-35.99 %
PEG Ratio
–
Return On Equity TTM
-115.71 %
Wall Street Target Price
19.4 USD
Revenue TTM
2 911 000 USD
Book Value
3.46 USD
Revenue Per Share TTM
Dividend Share
–
Quarterly Revenue Growth YOY
179.9 %
Dividend Yield
–
Gross Profit TTM
1 069 000 USD
Earnings per share
-3.57 USD
Diluted Eps TTM
-3.57 USD
Most Recent Quarter
II 2024
Quarterly Earnings Growth YOY
–
Profit Margin
–
Dividend Analytics 1K0
Dividend growth over 5 years
–Continuous growth
–Payout Ratio 5 years average
–Dividend History 1K0
1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate
–
Ex Dividend Date
–
Forward Annual Dividend Yield
–
Last Split Factor
–
Payout Ratio
–
Last Split Date
–
Dividend Date
–
Stock Valuation 1K0
1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
–
Forward PE
–
Enterprise Value Revenue
190.9702
Price Sales TTM
265.5179
Enterprise Value EBITDA
-1.9906
Price Book MRQ
6.3169
Financials 1K0
1 year
3 years
5 years
10 years
15 years
| Results | 2019 | Dynamics |
* The data for this period has not yet been published
Technical indicators 1K0
For 52 weeks
4.55 USD
22.5 USD
50 Day MA
14.79 USD
Shares Short Prior Month
4 023 236
200 Day MA
11.1 USD
Short Ratio
7.66
Shares Short
3 684 728
Short Percent
24.46 %
BeatStart